Wow Jeff you've moved on from just making stuff up to spending lord knows how much time to find a reference in some obscure long winded document that you admit is irrelevant to early access programs in Europe!
ANP are being advised by a firm that specialises in setting up Early access programs in Europe and have stated prices charged will be comparable to current MS medicines. There would be no point in going through this whole exercise if that weren't the case.
Your post was pointless... but you are fascinating!
Ann: ATL1102 Early Access Program for Patients with MS, page-71
Add PER (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
10.5¢ |
Change
0.005(5.00%) |
Mkt cap ! $94.66M | |||
| Open | High | Low | Value | Volume |
| 10.5¢ | 10.5¢ | 9.8¢ | $49.85K | 497.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 101000 | 9.8¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 10.5¢ | 282099 | 4 |
View Market Depth
| Last trade - 16.10pm 03/10/2024 (20 minute delay) ? |
| PER (ASX) Chart |